{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:20:37Z","timestamp":1787728837711,"version":"build-2784847793"},"reference-count":47,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The study purpose was to quantify the epidemiology, healthcare resource utilization (HCRU), costs, survival, and treatment patterns of myasthenia gravis (MG) in Canada using population\u2010based administrative data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted using administrative data in Ontario, Canada from 2013 to 2020. MG cases were identified using a validated algorithm. Outcomes included MG incidence and prevalence, myasthenic crisis incidence and prevalence, mortality, survival, HCRU, healthcare costs, and treatment patterns (among patients receiving public drug coverage; i.e., individuals \u2265\u200965\u2009years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 2601 individuals with MG (mean age 65.7\u2009years; 46.7% female). Standardized incidence remained stable (3.2\u20134.0 per 100,000), while prevalence increased from 36 to 42 per 100,000 from 2013\/14 to 2019\/20. Myasthenic crisis occurred in 8.9% of individuals over the study, with a post\u2010diagnosis incidence rate of 2.6 per 100 person\u2010years and 30\u2010day mortality of 28.1%. 5\u2010year overall survival was 75%, declining to 39% among those with crisis. Mean annual HCRU and direct costs were highest in the first\u2010year post\u2010diagnosis (10.0 specialists visits and CAD $31,693), decreasing in subsequent years. Mean crisis\u2010related costs were CAD $32,948 per person\u2010month in the first 90\u2009days after crisis. During the study among patients \u2265\u200965\u2009years, most (77.9%) received AChE inhibitors, and excluding AChE inhibitors, corticosteroids were the most common first\u2010line treatment (62.7%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MG imposes a substantial clinical and economic burden particularly among patients experiencing myasthenic crisis. These findings underscore the need for early intervention and improved access to advanced therapies to mitigate long\u2010term morbidity and healthcare costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.70694","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:28:26Z","timestamp":1787369306000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Myasthenia Gravis (\n                    <scp>MG<\/scp>\n                    ) Resource Utilization, Epidemiology, Survival, and Treatment Patterns (\n                    <scp>MG<\/scp>\n                    \u2010\n                    <scp>REST<\/scp>\n                    ): Estimating the Clinical and Economic Burden in Ontario, Canada"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5546-0221","authenticated-orcid":false,"given":"Carolina","family":"Barnett\u2010Tapia","sequence":"first","affiliation":[{"name":"Institute of Health Policy, Management and Evaluation University of Toronto  Toronto Canada"},{"name":"Division of Neurology, Department of Medicine University Health Network and University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kobina","family":"Quansah","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysegul","family":"Erman","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Nath","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Inc.  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Golden","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Inc.  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9929-3645","authenticated-orcid":false,"given":"Ryan","family":"Ng","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Inc.  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Sharma","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Inc.  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Breiner","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine University of Ottawa and the Ottawa Hospital Research Institute  Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120268"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1329200"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.002"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2015.10.009"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2025.04.028"},{"key":"e_1_2_11_8_1","first-page":"919","article-title":"Epidemiology of Myasthenia Gravis in Denmark, Finland and Sweden: A Population\u2010Based Observational Study","volume":"95","author":"Vissing J.","year":"2024","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207863"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181a41211"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008688"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061597"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001126"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24960"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1573-2"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10902-1"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066445"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11517-w"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00912-8"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.809999"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03014-5"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00498-8"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207937"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000375463"},{"key":"e_1_2_11_27_1","unstructured":"Statistics Canada \u201cVital Statistics Death Database\u2014Glossary \u201d(2020)."},{"key":"e_1_2_11_28_1","unstructured":"W. P.Wodchis K.Bushmeneva M.Nikitovic andI.McKillop \u201cGuidelines on Person\u2010Level Costing Using Administrative Databases in Ontario \u201d inWorking Paper Series Ontario ed. Network HSPR (2013)."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261983"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2008.341"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2020-0145"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.1.78"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2016.02.07"},{"key":"e_1_2_11_36_1","unstructured":"Statistics Canada \u201cLife Tables Canada Provinces and Territories 1980\/1982 to 2021\/2023 (Three\u2010Year Estimates) and 1980 to 2023 (Single\u2010Year Estimates).\u201d"},{"key":"e_1_2_11_37_1","unstructured":"CDA\u2010AMC Reimbursement Review \u201cPharmacoeconomic Report for Eculizumab (Solaris) \u201d (2020)."},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12588-7"},{"key":"e_1_2_11_39_1","unstructured":"CDA\u2010AMC \u201cReimbursement Recommendation for Efgartigimod Alfa (Vyvgart) \u201d (2024)."},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2353381"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27992"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-91372-7"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16367"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02727-0"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200335"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241237495"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/1941875210382918"},{"key":"e_1_2_11_48_1","first-page":"8","article-title":"CADTH Reimbursement Review: Efgartigimod Alfa (Vyvgart)","volume":"4","author":"Health CAfDaTi","year":"2024","journal-title":"Canadian Journal of Health Technologies"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70694","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.70694","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:30:37Z","timestamp":1787725837000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.70694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/ene.70694"],"URL":"https:\/\/doi.org\/10.1111\/ene.70694","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2025-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70694"}}